Ointment with bee moth larvae extract and propolis extract for prevention and integrated treatment of viral infection

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, namely an antiviral agent. An agent for influenza virus comprises an active substance in the form of an alcohol extract of bee moth larvae, an alcohol extract of propolis and an ointment base containing styrene maleic anhydride copolymer, Vaselin, emulsifier T-2, Cremophore RH-40 and Lutrol F-68, and purified water in certain proportions.

EFFECT: ointment shows manifested antiviral action on influenza virus.

3 dwg, 3 tbl, 6 ex

 

The present invention relates to medicine, namely to the pharmacy, and concerns the development of an ointment containing extracts of large larvae of the wax moth (LBVM) and propolis, and can be used for prevention and complex treatment of acute respiratory viral infections (ARVI), caused by the influenza virus.

Known antiviral agent-based recombinant interferon in the form of an ointment, gel, suppository, cream, liniment containing grease-forming the basis of adding nipagina and polyvinylpyrrolidone, and the trylon B, butylacetyl, DMSO and tween-80 [patent RU 2150291, 2000].

Known means in the form of a gel or ointment for external use, with anti-herpes activity, wound healing and antiviral action, which contains hyaluronic acid, trimekain, glycerin and polyethylene oxide [patent RU 2178693, 2002].

Known antiviral agent in the form of a gel containing leukocyte interferon of man as the basis of a 2%solution of a copolymer of styrene and maleic anhydride, nipagin [patent RU 2302881, 2007].

Known remedy for external use for the treatment of diseases of the skin and mucous membranes caused by herpes simplex virus, containing as an active ingredient the peptide SEQ ID NO:1 (allostatic-1), and as in pologitelnui substances glycerin, allantoin, urea, triethanolamine, carbopol 21, kemben [patent RU 2338553, 2008].

Known immunocorrigirutee tool for the treatment of diseases of viral etiology, which contains human recombinant interferon alpha and/or beta and/or gamma, anti-oxidant complex of tocopherol acetate and its derivatives, including water-soluble, and salts of ascorbic acid, calcium Pantothenate, anti-virus components, as well as support and formative components when a certain ratio of 1 g of the medicinal product, the tool includes as antiviral components - Arbidol and its derivatives, rimantadine, oseltamivir, ribavirin, an inosine pranobex (isoprinosine), glycyrrhizinic acid and its derivatives, nucleosides from series - famvir, valacyclovir, ganciclovir, valganciclovir, foscarnet, cidofovir, lobucavir, sorivudin, brivudin, antiretrovirus - lamivudine, zidovudine, lopinavir, stavudine. The tool is made in the form of a rectal-vaginal suppositories, gel, ointment, liquid [patent RU 2411039, 2011]. The invention provides a high therapeutic effect and a high degree of bioavailability.

Known antiviral drug in the form of ointment Acyclovir 5% (Registration number R N001595/01)containing 1 g of preparation: the active substance - acyclovi is - 0.05 g; excipients: propylene glycol, medical vaseline, vaseline oil, polyethylene oxide, emulsifier [Reference Vidal. Drugs in Russia. Attraversare, 2009, strb-316]. Ointment Acyclovir 5% is used as antiviral agents for treatment of herpes simplex skin, genital herpes, localized herpes zoster (secondary treatment); varicella.

Known oxolinic ointment is a synthetic drug, active ingredient - oksolina (1,2,3,4-tetrahydro-1,2,3,4-tetractinellida dehydrate). Released: 0.25% of oxolinic ointment in tubes of 10 g; and 0.50%, 1%, 2% and 3% oxolinic ointment in tubes of 10 g, 30 g and 50 g Flu and flu prevention. Viral diseases of the skin and eyes: viral rhinitis, keratoconjunctivitis, keratitis, herpes simplex and herpes zoster, genital warts, warts, molluscum contagiosum [http://www.citopsor.com/index.php?option=com_content&task=view&id=117; http://www.piluli.ru/product/Oksolinovaya_maz]. This tool has antimicrobial, bacteriostatic action, used in therapy for the prevention and treatment of SARS, however, the absorbability of the drug when applied externally insignificant, it does not have anti-inflammatory and prolonged action.

The closest analogue of the present invention is an ointment with ionol and propolis extract for treatment the inflammatory diseases in the field of gynecology, containing BHT, oil extract of propolis 15%, a copolymer of styrene with maleic anhydride and water, purified as the hydrophilic base in the following ratio, wt.%: BHT 5,0, oil extract of propolis 15% 5,0, a copolymer of styrene with maleic anhydride 2,0, purified water up to 100.0. This tool has a durable regenerating, anti-inflammatory, antiviral action, good fixation and a uniform distribution on the mucous surface when plugging the sick, convenient and hygienic in use [patent RU 2372093, 2009].

The objective of the invention is the development of effective antibacterial and antiviral agents, the expansion of the means of local treatment of SARS.

The technical result - the creation of new medicinal products domestic production in the form of ointments with severe prolonged anti-inflammatory antiviral regenerating and anti-bacterial action with good fixation on the mucous membrane of the nose and a uniform distribution on the surface, preventing side effects, convenience and hygiene applications.

This technical result is achieved by the fact that the tool against influenza virus containing propolis extract as an active substance in an amount of 5.0 wt.% and ointment base, is with a copolymer of styrene with maleic anhydride in the amount of 2.0 wt.% and purified water to 100 according to the invention additionally contains as active substance alcohol extract large larvae of the wax moth, as propolis extract contains alcohol extract of propolis and the base further comprises petrolatum, emulsifier T-2, cremophor RH40 and lotrel F-68 in the following ratio, wt.%:

alcohol extract of propolis5,0
alcohol extract large larvae of the wax moth5,0
a copolymer of styrene with maleic anhydride2,0
vaseline4,8
emulsifier T-21,6
cremophor RH401,6
lotrel F-682,0
purified water100

The invention is illustrated in the figure, which shows the effect of different concentrations of the excipients of cremophor RH-40 on the release of the extracts.

All components included in the composition of ointments that are allowed for medical use.

Lotrel F-68 (Lutro F-68), BASF (Germany) 9003-11-6 improves dissolution (solubilization) of active substances in the composition.

Cremophor RH-40 (Cremofor® RH-40) BASF (Germany) No. 013635/01-2002 ethoxylated hydrogenated castor oil, improves the structure of the solvent increases the bioavailability of the incorporated active substances through the surface-active properties.

Emulsifier T-2 (Russia) THE 18-17-05-76.

A copolymer of styrene with maleic anhydride (SMA) or modified stromal "Plastigel" redkosty swollen polymer (TU 6-01-02274010913-01) is the product of copolymerization of styrene with maleic anhydride (SMA)modified with ammonia, is a white powder. The appearance of 2% solution of a copolymer of styrene in water - clear or slightly cloudy liquid - gel. Soluble in water swells, soluble in glycerin, alcohol. SMA in the form of an aqueous solution of 2% gel has a pronounced antiviral effect "for the treatment of herpetic keratitis" (patent No. 2135187, 1999, IPC A61K 31/765).

Introduction to the composition of propolis extract and extract large larvae of the wax moth increases antimicrobial activity ointments, contributes to the manifestation of antiviral, anti-inflammatory, reparative action and prolonged effect of the dosage form.

In addition to the manifestations known the properties of each component of the proposed structure together strengthens their influence, because, obviously, the effect of their synergies.

As a result of experimental studies, it was found that emulsion base provides reliable fixation of the drug to the mucosal surface when natalina application, contributes to a better distribution of extracts based, emulsion base increases the bioavailability of extracts due to surface-active properties. Giving the drug form of ointment provides convenience and hygiene applications, the drug forms Nicolaus film when natalina application, has expressed a prolonged effect and storage stability.

Example 1. The composition 100,0 ointment: the alcoholic extract of propolis - 5; extract large larvae of the wax moth alcoholic - 5; petroleum jelly - 4,8; emulsifier T-2 - 1,6; cremophor RH40 - 1,6; Lutron F-68 - 2,0; SMA - 2,0; purified water up to 100.0.

Get the ointment in the following way.

In purified water dissolve lotrel add SSM to obtain a gel. Melted on a water bath emulsifier T-2, vaseline, cremophor. Alloy and gel unite. The mixture is thoroughly mixed, add the extract large larvae of the wax moth and propolis extract. The resulting homogeneous ointment, satisfactory consistency, easily distributed on the skin surface, stable, with a density of 1.1 g/cm3pH ointment to 6.0. MAZ is easily applied on the mucous membranes of the covers with the formation of a smooth continuous stroke, Lis has a prolonged action, as well as the convenience and hygiene of application due to the proposed composition of the ingredients.

We studied the effect of concentration of cremophor RH40 - 1.6 g on the release of the extracts in vitro by thin layer chromatography (TLC). The definition of pharmaceutical availability were carried out in a solvent system selected earlier (table 1) ethyl acetate:ethanol:ammonia (85:10:5) in a chromatographic chamber bottom-up fashion on the plates of the brand "Silufol". Time-keeping records in the chamber was the same and amounted to 13 minutes.

Thus, the optimum content of cremophor in the ointment is the value of 1.6% (figure).

Example 2. The composition 100,0 ointment: the alcoholic extract of propolis - 5; extract large larvae of the wax moth alcoholic - 5; petroleum jelly - 4,8; emulsifier T-2 - 1,6; cremophor RH40 - 1,0; Lutron F-68 - 2,0; SMA - 2,0; purified water up to 100.0.

Make an ointment in a similar way. The resulting homogeneous ointment, satisfactory consistency, easily distributed on the skin surface, stable, density -1,1 g/cm3pH ointment to 6.0. The ointment is easy to apply on the mucous membranes of the covers with the formation of a smooth continuous stroke, has expressed prolonged action, as well as the convenience and hygiene of application due to the proposed composition of the ingredients.

We studied the effect of concentration the AI cremophor RH40 - 1.0 g on the release of the extracts in vitro by thin layer chromatography (TLC). The definition of pharmaceutical availability were carried out in a solvent system selected earlier (table 1), ethyl acetate:ethanol:ammonia (85:10:5) in a chromatographic chamber bottom-up fashion on the plates of the brand "Silufol". Time-keeping records in the chamber was the same and amounted to 13 minutes.

Thus, the number of 1.0 g of cremophor RH 40 in the ointment is not enough, as marked by reduced release of active substances - extracts of large larvae of the wax moth and propolis extract (figure).

Example 3. The composition 100,0 ointment: the alcoholic extract of propolis - 5; extract large larvae of the wax moth alcoholic - 5; petroleum jelly - 4,8; emulsifier T-2 - 1,6; cremophor RH40 - 2,0; Lutron F-68 - 2,0; SMA - 2,0; purified water up to 100.0.

Make an ointment in a similar way. The resulting homogeneous ointment, satisfactory consistency, easily distributed on the skin surface, stable, with a density of 1.1 g/cm3pH ointment to 6.0. The ointment is easy to apply on the mucous membranes of the covers with the formation of a smooth continuous stroke, has expressed prolonged action, as well as the convenience and hygiene of application due to the proposed composition of the ingredients.

We studied the effect of concentration of cremophor RH40 - 1.0 g on the release of the extracts in vitro by the method of thin-layer is cromatografia (TLC). The definition of pharmaceutical availability were carried out in a solvent system selected earlier (table 1), ethyl acetate:ethanol:ammonia (85:10:5) in a chromatographic chamber bottom-up fashion on the plates of the brand "Silufol". Time-keeping records in the chamber was the same and amounted to 13 minutes.

Thus, the amount of 2.0 g of cremophor RH40 in the ointment is redundant, as noted reduced release of active substances - extracts of large larvae of the wax moth and propolis extract (figure).

Example 4. The composition 100,0 ointment: the alcoholic extract of propolis - 5; extract large larvae of the wax moth alcoholic - 5; petroleum jelly - 4,8; emulsifier T-2 - 1,6; cremophor RH40 - 1,0; Lutron F-68 - 2,0; SMA - 1,0; purified water up to 100.0.

Make an ointment in a similar way. The resulting homogeneous ointment, liquid consistency, density 0.9 g/cm3pH ointment to 6.0. When applying drains from the surface, smear uneven, there is no effect of the extension.

Example 5. The composition 100,0 ointment: the alcoholic extract of propolis - 5; extract large larvae of the wax moth alcoholic - 5; petrolatum 22, 0mm; emulsifier T-2 - 10,0; cremophor RH40 - 10,0; Lutron F-68 - 8,0; SMA - 2,0; purified water up to 100.0.

Get the ointment in the following way.

In purified water add SSM to obtain a gel. Melted on a water bath emulsifier T-2, vaseline, cremophor, lotrel. Alloy and gel unite. The mixture is thoroughly mixed, add extract large larvae of the wax moth and propolis extract. The resulting ointment is homogeneous, dense consistency, with work distributed on the skin surface, stable, with a density of 1.6 g/cm3pH ointment to 6.0. To apply the ointment on the mucous coverings difficult, uneven smear.

Example 6. The composition 100,0 ointment: propolis extract alcohol - 5; extract large larvae of the wax moth alcohol - 5; petroleum jelly - 20,0; emulsifier T-2 - 10,0; cremophor RH40 - 10,0; Lutron F-68 - 20,0; purified water up to 100.0.

Get the ointment in the following way.

Melted on a water bath emulsifier T-2, vaseline, cremophor, lotrel. In parts add purified water. The mixture is thoroughly mixed, add the extract large larvae of the wax moth and propolis extract. The resulting homogeneous ointment, unsatisfactory viscous consistency, not evenly distributed on the surface of the skin, forming a viscous film, stable, with a density of 1.6 g/cm3pH ointment to 6.0. To apply the ointment on the mucous coverings difficult, uneven smear.

The given examples show that the optimal from the point of view of consistency, ease of use, effectiveness of treatment is the composition described in example 1.

Determination of antimicrobial activity ointment containing 5% propolis extract and 5% extract large larvae of the wax moth, conducted according to customers is avanian, requirements for dosage forms, namely antibacterial properties on the composition of the ointment of example 1. Studies of the antibacterial efficacy of the ointment was carried out according to the method described in the global Fund XII ed., CFC 42-0068-07 (Table 2).

The proposed dosage form is an ointment containing propolis extract and extract large larvae of the wax moth, easy to use and has a wide field of use in the prophylaxis and complex treatment of acute respiratory viral infection caused by the influenza virus.

Agent against influenza virus containing propolis extract as an active substance in an amount of 5.0 wt.% and ointment base comprising a copolymer of styrene with maleic anhydride in the amount of 2.0 wt.% and purified water, characterized in that it additionally contains as active substance alcohol extract large larvae of the wax moth, as propolis extract contains alcohol extract of propolis and the base further comprises petrolatum, emulsifier T-2, cremophor RH40 and lotrel F-68 in the following ratio, wt.%:

alcohol extract of propolis5,0
alcohol extract large larvae of the wax moth5,0
a copolymer of styrene with maleic anhydride2,0
vaseline4,8
emulsifier T-21,6
cremophor RH401,6
lotrel F-682,0
purified water100



 

Same patents:

FIELD: medicine, pharmaceutics.

SUBSTANCE: method under the invention provides detoxification and polymerisation of antibiotics in 0.15±0.05% glutaric aldehyde at 38-40°C for 3-5 days, and then in 0.1% alkyl dimethyl benzyl ammonium chloride at 38-40°C for 3-5 days.

EFFECT: method provides effective bactericidal, virusocidal and fungicidal action of antibiotics and enables extending their therapeutic spectrum of application.

1 tbl, 4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to solvated and non-solvated crystalline forms of 20,23-dipiperidinyl-5-O-micaminosyl-tylonolide having characteristics specified in the description. The application materials also present methods for preparing such crystalline forms. The invention declares a pharmaceutical composition for treating hemorrhagic septicemia, ruminant respiratory disease and swine respiratory disease, containing 20,23-dipiperidinyl-5-O-micaminosyl-tylonolide in the solid form wherein a therapeutically effective amount of 20,23-dipiperidinyl-5-O-micaminosyl-tylonolide in the composition consists of a substantially pure phase of the crystalline form or at least 50% of 20,23-dipiperidinyl-5-O-micaminosyl-tylonolide in the composition consists of a crystalline form.

EFFECT: use of the therapeutically effective amount of the pharmaceutical composition for preparing the drug for treating hemorrhagic septicemia, ruminant respiratory disease and swine respiratory disease.

13 cl, 23 ex, 22 tbl, 40 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely dental decontamination agents. A formulation for disinfection of removable dentures represents a solution of cetrimide, silver ions, a stabiliser, a perfume, chitosan succinate, water under certain proportions (wt %).

EFFECT: invention provides more effective disinfection and cleaning of removable blade dentures ensured by a wide spectrum of antimicrobial action on gram-positive, gram-negative microorganisms, fungicidal action on yeast-like fungi, including gen Candida, antiviral action (on enveloped and non-enveloped viruses), micobacteria, as well as provides disadhesion action, the absence of a negative effect on a dental plate surface, reduced time of exposition and non-corrosion activity.

2 tbl, 5 ex

FIELD: chemistry.

SUBSTANCE: invention relates to biotechnology, specifically obtaining immunogens from Neisseria meningitides and can be used in medicine. Disclosed is protein which is 80% or more identical to amino acid sequence SEQ ID NO:19, and an immunogenic composition with said protein.

EFFECT: invention enables to use said protein for effective prevention or treatment of bacterial meningitis.

6 cl, 5 dwg, 28 tbl

FIELD: medicine.

SUBSTANCE: invention relates to veterinary science. There are involved the intrauterine infusions of the ozonised emulsion 100.0 ml consisting of equal portions of cod liver oil and linseed infusion every 48 hours until clinical recovery is observed.

EFFECT: method is simple and high-effective in treating endometritis in cows.

9 tbl, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to veterinary science. The agent contains, wt %: wildflower honey 3.0-5.0, pine turpentine 5.0-8.0, melted (cow) butter 12.0-15.0, anaesthesine 0.5-1.0, glycerol 0.5-1.5, ethanol 20.0-25.0, potassium iodide 2.0-2.5, salicylic acid 3.0-5.0, 9% vinegar 6.0-8.0, Novocaine (powder) 1.0-1.5, distilled water - the rest.

EFFECT: use of the declared agent enables higher clinical effectiveness in actinomycosis and necrobacteriosis, improved immunobiological properties of animal's body, reduced length of recovery.

1 tbl, 4 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine and aims at treating acute and aggravated chronic laryngitis. What is involved is specific antibioticotherapy per os with additional examination of microflora starting from the 3rd-5th day of the therapy followed by instillations of specific, result-related bacteriophagues into the larynx in the amount of 0.5-1.0 ml in acute laryngitis for 7-10 days, and in aggravations for 10-14 days.

EFFECT: method provides higher clinical effectiveness ensured by a lower number of side effects and complications, and a reduced length of treatment.

16 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, and concerns a universal vaccine for treating and preventing Lyme disease to be applied in veterinary science, based on a whole-cell bacterial vaccine or bacterial lysates or purified preparations, containing the three most pathogenic genospecies Borrelia burgdorferi sensu stricto, Borrelia afzelii and Borrelia garinii, each of which simultaneously contains both immunogenic protective proteins of the outer membranes OspA and OspC.

EFFECT: invention provides developing the protective immunity against a natural tick-borne infection of the three most pathogenic genospecies Borrelia burgdorferi sensu stricto, Borrelia afzelii and Borrelia garinii.

9 cl, 1 ex, 12 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to chemical-pharmaceutical industry and presents a moxifloxacin aqueous formulation for parenteral introduction containing an active substance: moxifloxacin hydrochloride, water for injections and other ingredients used for parenteral introduction differing by the fact that said ingredients are presented by sodium ascorbate and sodium metabisulphite in the following proportions, g/l: moxifloxacin hydrochloride 15-25; sodium ascorbate 0.05-1; sodium metabisulphite 0.1-2; water for injections up to 1 l.

EFFECT: invention provides creating a therapeutic agent providing a high therapeutic effect in prevention and treatment of bacterial infections by reduction of infectious and inflammatory processes in tissues, and reduced length of recovery.

2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to new antibacterial compounds of formula I

wherein R1 represents halogen or alkoxy group; each U and W represents N; V represents CH, and R2 represents H or F, or each U and V represents CH; W represents N, and R2 represents H or F, or U represents N; V represents CH; W represents CH or CRa, and R2 represents H, or also when W represents CH, may represent F; Ra represents CH2OH or alkoxycarbonyl; A represents group CH=CH-B, a binuclear heterocyclic system D, phenyl group which is mono-substituted in the position 4 by C1-4 alkyl group, or phenyl group which is di-substituted in positions 3 and 4 wherein each of two substitutes is optionally specified in a group consisting of C1-4 alkyl and halogen; B represents mono- or di-substituted phenyl group wherein each substitute is a halogen atom; D represents group

wherein Z represents CH or N, and Q represents O or S; or to salts of such compounds.

EFFECT: compounds are used for treating bacterial infections.

13 cl, 2 tbl, 25 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to chitosan carboxyalkylamide hydrogel and may be used for cosmetic and dermatological treatment of skin burns. Chitosan carboxyalkylamide hydrogel of pH close to that of skin and making 6.5 to 7.2 contains 40 to 90 mole % of the groups of N-carboxyalkylaminde D-glucosamine of formula (I) wherein n represents an integer 1 to 8, 60 to 10 mole % of the protic groups of D-glucosamine, and 5 to 15 mole % of the groups of N-acetyl-D-glucosamine. A method for preparing said hydrogel involves preparing an acid solution of chitosan of a degree of acetylation of 85 to 95%, providing a reaction of produced additive chitosan salt in an aqueous solution of diorganic acid and correcting pH of the prepared solution.

EFFECT: preparing the anhydrous product of chitosan carboxyalkylamide prepared by hydrogel dehydration.

12 cl, 1 dwg

FIELD: medicine.

SUBSTANCE: what is presented is the use of xenon in the form of an agent for external therapy of chronic recurrent inflammatory dermatopathies prepared by extra pure grade xenon saturation of a fatty base.

EFFECT: what is shown is considerable reduction of an inflammatory reaction on the second therapeutic day in such polygenic chronic inflammatory diseases, as psoriasis, atopic dermatitis, acne, acne rosacea, eczema.

4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmacy, namely agents based on herbal raw material possessing pecilomycotic action. A sage kerosene ointment contains kerosene extract of air-dried sage leaves, Vaselin taken in certain proportions.

EFFECT: ointment possess effective antimycotic action.

4 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to medicine, namely to a pharmaceutical composition for local application. The composition contains chondroitin sulphate, hyaluronidase, glucosamine hydrochloride, liposome and pharmaceutically acceptable carriers and excipients in the amounts specified in the patent claim. The composition may additionally contain capsaicin.

EFFECT: pharmaceutical composition according to the invention is characterised by fast skin penetration of the ingredients.

3 cl, 4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmaceutical industry, to creation of wound-healing ointment. Ointment for treatment of bitten wounds includes lidocaine hydrochloride, sea-buckthorn oil, water-free lanolin, medicinal purified Vaseline, metronidazole, clindamycin, rifampicin and trombolisin.

EFFECT: ointment ensures accelerated passage of active substances through inter-tissue space into tissue depth and quickly suppresses various microflora in bitten wound.

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to field of veterinary, in particular to veterinary surgery, and can be applied in treatment of purulent wounds in animals. Medication for treatment of purulent wounds in animals includes active substance and ointment base - polyethylene oxide-1500 and polyethyl oxide-400. Active substance is a product of dry sublimation of birch chaga mushroom, mixed with polyethylene oxide-400 and polyethyleneoxide-1500 in ratio 1.25:4:1 respectively at temperature 39…4°C.

EFFECT: application of claimed medication for treatment of purulent wounds in animals will make it possible to increase efficiency of treatment of purulent skin-muscular wounds, with reduction of financial expenditures and terms of wound healing in animals.

1 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: dosage form for local application in the form of cream or ointment contains as effective amount of voriconazole or its pharmaceutically acceptable salt, or a pharmaceutical carrier. Said dosage form of voriconazole contains max. 3 wt % of water. What is also described is a method for preparing the dosage form of voriconazole for treating local and non-systemic mycotic infections in an individual.

EFFECT: dosage form for local application under the invention maintains storage stability at temperature approximately 40°C and relative humidity approximately 75% for at least three months and has total storage impurity content is no more than 9 wt % as related to total weight of the dosage form.

12 cl, 1 dwg, 30 ex

FIELD: medicine.

SUBSTANCE: offered invention refers to medicine, namely dentistry, and may be used for treating children suffering maxillofacial abscesses and phlegmons. That is ensured by opening of a suppurative focus, wound bathing and drainage. With underlying conventional antibacterial therapy, an ointment containing furacilin, lidocaine and dibunol as active agents and a styrene maleic anhydride copolymer, Lutrol F-127 and purified water in certain proportions as an ointment base is introduced in the suppurative cavity. Furacilin - 0.2, Lidocaine - 5.0, Dibunol - 5.0, Styrene maleic anhydride copolymer - 2.0, Lutrol F-127 2.0 and Purified water to 100.0.

EFFECT: use of the given invention reducing length of wound cleaning and epithelisation in children due to the use of the ointment in presented proportions.

2 ex

FIELD: medicine.

SUBSTANCE: phospholipid emulsion contains lecithin with the phosphatidylcholine content min. 60%, ethanol, water and diclofenac sodium in the amounts specified in the patent claim. The phospholipid emulsion represents liposomes (nanosomes) of a mean diameter of 20 to 500 nm. The composition is used for the liposomal introduction of biologically active substances and/or drugs into a human body. The emulsion nanosomes may additionally contain one or more substances specified in a group: carotinoids, flavonoids, vitamins, resveratrol, vitamin-like substances, cartilage protectors, amino acids, preserving agents.

EFFECT: emulsion provides selectivity of the effect of the active compound on body tissues, enables adjusting skin penetration rate of the active substance, dosing the active ingredients, increasing bioavailability of the active substances, reducing their negative effect of the body.

13 cl, 7 dwg, 1 tbl, 11 ex

FIELD: medicine.

SUBSTANCE: 10 minutes before grafting, donor skin 0.2-0.3 mm is coated with Tisol gel mixed with ozonised sea buckthorn oil. Then, 10 minutes later, the residual mixture is removed; the donor skin surface is treated with spirits, and grafting procedure is started.

EFFECT: method provides better microcirculation within the donor area, ensures bactericidal action, higher tissue and graft oxygenation.

1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to medicine, namely to medication for promotion of survival of obtained from bone marrow mesenchymal stem cells in vivo and differentiation in cadiomyocytes. Application of traditional Chinese medical composition for obtaining medication for promotion of survival of obtained from bone marrow mesenchymal stem cells in vivo and differentiation in cadiomyocytes. Traditional Chinese medication composition (versions). Method of treatment and prevention of cardiovascular disease, including introduction to patients who need it of efficient quantity of traditional Chinese medical composition, and mesenchymal stem cells, obtained from bone marrow.

EFFECT: composition is efficient for promotion of in vivo survival of obtained from bone marrow mesenchymal stem cells and their differentiation in cardiomyocytes.

15 cl, 8 dwg, 1 tbl, 1 ex

Up!